舒肝解郁胶囊与帕罗西汀治疗帕金森病伴抑郁的疗效比较  

Clinical efficacy of paroxetine and Shugan Jieyu capsule on Parkinson disease with depression

作　　者：张小东[1] 刘超[1] 余巨明[1] 

机构地区：[1]川北医学院附属医院神经内科,南充637000

出　　处：《世界临床药物》2016年第3期185-189,共5页World Clinical Drug

摘　　要：目的评价舒肝解郁胶囊和帕罗西汀对帕金森病(PD)伴抑郁患者的临床疗效。方法 75例PD伴抑郁患者随机分为帕罗西汀组、舒肝解郁胶囊组和对照组,每组25例。3组均同时进行PD常规治疗,帕罗西汀组给予帕罗西汀治疗,舒肝解郁胶囊组口服舒肝解郁胶囊,均为期6周;对照组不接受任何抗抑郁药物治疗。治疗3周和6周分别以抑郁自评量表(SDS)、汉密尔顿抑郁量表(HAMD)和改良Webster症状评分量表(简称Webster评分)对3组患者进行抑郁和PD疗效评价,同时观察治疗组患者不良反应。结果治疗第3和第6周时,根据SDS评分各组有效率:对照组为8%及12%,帕罗西汀组为40%及64%,舒肝解郁胶囊组为44%及60%;根据HAMD评分各组有效率:对照组为8%及20%,帕罗西汀组为44%及72%,舒肝解郁胶囊组为44%及64%;根据Webster评分各组有效率:对照组为16%及28%,帕罗西汀组为28%及64%,舒肝解郁胶囊组为24%及60%;与对照组比较,帕罗西汀组和舒肝解郁胶囊组治疗3周和6周有效率均显著提高(P<0.05);帕罗西汀组和舒肝解郁胶囊组治疗6周有效率均显著高于治疗3周,且差异具有统计学意义(P<0.05);帕罗西汀组和舒肝解郁胶囊组各项评分组间比较差异均无统计学意义(P>0.05)。各组患者未见明显不良反应。结论舒肝解郁胶囊治疗PD伴抑郁疗效明确,安全性好。Objective To evaluate the clinical efficacy of paroxetine and Shugan Jieyu capsule on Parkinson disease（PD） patients with depression. Methods A total of 75 PD patients with depression were randomly divided into paroxetine group, Shugan Jieyu capsule group and control group（25 cases in each group）. All 3 groups were treated with conventional PD treatment methods. While Paroxetine group was additionally treated with paroxetine,Shugan Jieyu capsule group was additionally treated with Shugan Jieyu capsule, and the control group was treated with conventional therapy only. Hamiltion depression scale（HAMD）, self-rating depression scale（SDS）and modified Webster score were used to evaluate the clinical effect of three groups in 3 weeks and 6 weeks. The adverse reactions after treatment were examined. Results After 3 weeks and 6 weeks of treatment, based on SDS score, the effective rate in paroxetine group were 40% and 64% respectively, and in Shugan Jieyu capsule group were 44% and 60%, which were significantly higher than those in control group（8% and 12%）, the difference was statistically significant（P〈0.05）. According to HAMD score, the effective rate on 3rd week and 6th week treatment were 44% and 72% in paroxetine group, were 44% and 64% in Shugan Jieyu capsule group, whichwere significantly higher than those in control group（8% and 20%）, the difference was statistically significant（P〈0.05）. According to Webster score, the effective rate on 3rd week and 6th week treatment were 28% and 64% in paroxetine group, were 24% and 60% in Shugan Jieyu capsule group, which were significantly higher than those in control group（16% and 28%）, the difference was statistically significant（P〈0.05）. The effective rate of paroxetine group and Shugan Jieyu capsule group in 6 week treatment were significantly higher than those in 3 week treatment（P〈0.05）. There were no statistically significant difference in the scores between paroxetine group and Shugan Jieyu capsule group, and were no

关 键 词：舒肝解郁胶囊 帕罗西汀 帕金森病(PD) 抑郁 

分 类 号：R971.43[医药卫生—药品] R749.3[医药卫生—药学]